TACSTD2 and neoplasm: Other promising ADCs are under investigation such as Datopotamab deruxtecan (Dato-DXd or DS-1062a) and SKB264 (AKB264) [23,24], both of which explicitly target Trop2-expressing cancer cells to ensure precise delivery of the drug payload to the tumor.